Latest Recruitment News

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

GBM Resources has raised $13 million through a two-tranche placement, repaid $6.2 million in convertible debt, and completed a significant board restructure to accelerate exploration at its Drummond Basin gold projects.

Next Science reports a 10% decline in quarterly product sales but advances a $50 million asset sale to Demetra Holdings, signaling a pivotal shift in its business strategy.

BauMart Holdings reports progress in AI-enhanced international recruitment, sustainable building materials development, and expansion into off-grid energy solutions, alongside a partial rights issue raising $180,000.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Future Metals NL has raised A$4.2 million and entered a strategic MOU with Zeta Resources to explore processing its Eileen Bore and Panton ores at the Savannah Mine plant, signalling a new phase of development amid rising PGM prices.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

IGO Limited reported robust operational performance in Q4 FY25 with improved safety and higher production at Greenbushes and Nova, while facing significant impairment at its Kwinana lithium refinery.